Search results for " Bladder"

showing 10 items of 396 documents

Where will the next generation of medical treatments for overactive bladder syndrome come from?

2020

This review article discusses the medical need for improved medical treatments of overactive bladder syndrome, and the hurdles and research required to address that need. Currently, few overactive bladder syndrome patients stay on long-term treatment, largely because efficacy expectations are not met, and tolerability is considered insufficient for the chronic treatment of a non-life-threatening condition. Therefore, a medical need exists for improved tolerability and, even more importantly, improved efficacy. It is unlikely that major improvements of efficacy and tolerability can be achieved within the currently approved drug classes. Work in experimental animals suggests that many causes …

medicine.medical_specialtyUrinary Bladder Overactivebusiness.industryUrology030232 urology & nephrology610 MedizinEfficacy expectationsOveractive bladder syndromeApproved drugReview article03 medical and health sciences0302 clinical medicineTolerabilityDrug development030220 oncology & carcinogenesis610 Medical sciencesmedicineAnimalsHumansBiomarker (medicine)Treatments for overactive bladderIntensive care medicinebusiness
researchProduct

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

2001

Objective  To determine the need to standardize the number and location of lymph nodes to be removed during radical cystectomy in patients with invasive bladder carcinoma. Patients and methods  The pelvic lymph nodes from 447 patients (mean age 62.8 years) who underwent radical cystectomy between 1986 and 1997 were evaluated. The number of lymph nodes was correlated with the depth of invasion of the primary tumour (pT), occurrence of nodal metastases, clinical outcome, the operating surgeons and the pathologists dissecting the nodes. Results  The clinical follow-up was available for 302 patients (mean follow-up 38.7 months). The mean (range) number of lymph nodes removed was 14.7 (1–46). Th…

medicine.medical_specialtyUrinary bladderBladder cancerbusiness.industryUrologymedicine.medical_treatmentmedicine.diseaseSurgeryCystectomyTransitional cell carcinomamedicine.anatomical_structuremedicineCarcinomaLymphadenectomyLymphRadiologybusinessLymph nodeBJU International
researchProduct

ORTHOTOPIC BLADDER SUBSTITUTION IN WOMEN: FUNCTIONAL EVALUATION

1999

AbstractPurpose: Orthotopic bladder substitution following cystectomy in women has recently been introduced at some specialized centers. Studies of such a procedure should consider the oncological and functional outcomes. We analyzed only the functional results of orthotopic bladder substitution since followup is too short (about 2 years) for a valid oncological assessment.Materials and Methods: From October 1994 to November 1997, 60 women with a mean age of 48.3 years underwent standard radical cystectomy and orthotopic diversion (ileal W-neobladder with subserous tunnel in 47 and hemi-Kock reservoir in 13). The oncological criterion was organ confined invasive bladder cancer.Results: Ther…

medicine.medical_specialtyUrinary bladderIleusbusiness.industryUrologyFistulaDeep veinmedicine.medical_treatmentPerioperativemedicine.diseaseThrombosisPulmonary embolismSurgeryCystectomymedicine.anatomical_structureMedicinebusinessJournal of Urology
researchProduct

Intravesical Treatment of Superficial Urinary Bladder Tumours with Adriamycin

1980

Personal experience resulted in the observation that intravesical Adriamycin (ADM) is effective in some patients with multiple or diffuse papillary bladder tumours. A review of the literature shows that similar results have been obtained elsewhere, especially in Japan and Sweden. The response rate was higher if single doses of at least 50 mg were employed. Intravesical instillations of ADM appear to be valuable also in the treatment of carcinoma in situ and in prophylactic treatment after transurethral resection (TUR) of papillary bladder tumours.

medicine.medical_specialtyUrinary bladderbusiness.industryCarcinoma in situUrologymedicine.diseaseResectionNeck of urinary bladderTransitional cell carcinomaIntravesical treatmentmedicine.anatomical_structureIntravesical instillationmedicinebusinessProphylactic treatment
researchProduct

Development of Bladder Carcinoma Following Portacaval Shunt in Rats

1987

Portacaval anastomosis (PCA) was first introduced by Eck (1877) and was investigated in a number of different animals. Lee et al. (1961; 1974) published a reliable method with low mortality in rats. The occurrence of urolithiasis in rats following portacaval anastomosis happened to be noticed by chance. It was published by Herz et al. (1972a, 1972b, 1973), who defined the portacaval shunt rat as an experimental model. Heine et al. (1979) described dysplastic and neoplastic changes of the bladder mucosa following portacaval anastomosis. His findings were confirmed by Duy et al. (1981); Grun et al. (1982), and Dubuisson et al. (1984). However, Wallace et al. (1984) found papillary hyperplasia…

medicine.medical_specialtyUrinary bladderbusiness.industryPortacaval anastomosisUrologyPortacaval shuntmedicine.diseasemedicine.anatomical_structureBladder NeoplasmmedicineCarcinomaBladder stonesbusinessBladder stoneUpper urinary tract
researchProduct

The mainz-pouch (mixed augmentation ileum 'n zecum) for bladder augmentation and continent diversion

1985

The ideal urinary reservoir constructed from bowel material should be a low-pressure system with a high capacity, capable of preventing upper tract deterioration resulting from ureteral obstruction or reflux. It should achieve reliable control of continence and assure easy emptying of the reservoir. In the Mainz-pouch, the combination of cecum and ileum, the latter of which is able to absorb pressure waves created by the cecum, produces a low-pressure system with a high capacity immediately postoperatively. By incorporating large bowel in our pouch, ureteral implantation can be done using a simple and reliable standard antireflux technique with a submucosal tunnel. The Mainz-pouch has been …

medicine.medical_specialtyUrinary bladderbusiness.industryUrologyUrinary systemmedicine.medical_treatmentUrinary diversionInvaginationSurgeryCystectomymedicine.anatomical_structureBladder augmentationmedicinePouchbusinessContinent Urinary DiversionWorld Journal of Urology
researchProduct

Follow-up results of embolization therapy for palliation of incurable bladder carcinoma

1985

Embolization therapy of the renal artery (N=10), hypogastric arteries (N=18) and ureter (N=24) was performed in 41 patients with incurable bladder carcinoma for palliation of gross hematuria and severe dysuria. Careful follow-up of the patients until death gave a mean survival time of 12.3 months after embolization; 6 patients are still alive. The results show that embolization therapy is justified for management of bleeding and dysuric complaints. Ureteral occlusion alone has almost no effect on hematuria. Combined embolization procedures yield better results than occlusion of the vessels or the ureter. Ureteral occlusion with a detachable balloon is superior to embolization with tissue ad…

medicine.medical_specialtyUrinary bladderbusiness.industryUrologymedicine.medical_treatmenturologic and male genital diseasesmedicine.diseaseInternal iliac arteryfemale genital diseases and pregnancy complicationsSurgerymedicine.anatomical_structureUretermedicine.arteryOcclusionCarcinomaMedicineDysuriaRadiologyEmbolizationRenal arterymedicine.symptombusinessWorld Journal of Urology
researchProduct

Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.

2020

Abstract Background Muscle-invasive bladder cancer (MIBC) is the second most common genitourinary malignancy, and is associated with high morbidity and mortality. Recently, molecular subtypes of MIBC have been identified, which have important clinical implications. Objective In the current study, we tried to predict the molecular subtype of MIBC samples from conventional histomorphology alone using deep learning. Design, setting, and participants Two cohorts of patients with MIBC were used: (1) The Cancer Genome Atlas Urothelial Bladder Carcinoma dataset including 407 patients and (2) our own cohort including 16 patients with treatment-naive, primary resected MIBC. This resulted in a total …

medicine.medical_specialtyUrology030232 urology & nephrologyH&E stainDiseaseMalignancy03 medical and health sciences0302 clinical medicineDeep LearningCarcinomamedicineHumansNeoplasm InvasivenessBladder cancerReceiver operating characteristicbusiness.industryDeep learningmedicine.diseaseMolecular Diagnostic TechniquesUrinary Bladder Neoplasms030220 oncology & carcinogenesisHistopathologyArtificial intelligenceRadiologybusinessForecastingEuropean urology
researchProduct

Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis.

2003

Abstract Objective: Pathologists play a pivotal role in the diagnosis and in the report of the pathological features related to prognosis. Methods: To meet these endpoints, the following issues must be accomplished: adequate information about the patient history, proper handling of the specimens, identification of the reliable histopathological techniques necessary to reach the more detailed diagnostic information and evaluate the prognostic variables, and a standardized pathological report. Results: Recent efforts to standardize the histopathological evaluation have generated significant confusion among the urological and pathological communities as well. No consensus has been achieved abo…

medicine.medical_specialtyUrologyBiopsySpecimen HandlingmedicineHumansMedical historyKidney PelvisPhysician's RoleGrading (tumors)Neoplasm StagingBladder cancerPathology Clinicalbusiness.industryUreteral NeoplasmsAnatomical pathologyProfessional PracticePathology Reportmedicine.diseasePrognosisKidney NeoplasmsSurgerySquamous carcinomamedicine.anatomical_structureEpidermoid carcinomaUrinary Bladder NeoplasmsRadiologybusinessRenal pelvisEuropean urology
researchProduct

The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder dis…

2014

Highlights • Muscarinic receptors increase smooth muscle tone in airways and urinary bladder. • β-Adrenoceptors relax smooth muscle tone and oppose muscarinic contraction. • Opposition involves transmitter release, signal transduction and receptor expression. • This supports the combined use of muscarinic antagonists and β-adrenoceptor agonists.

medicine.medical_specialtyUrologyDiseaseMuscarinic AntagonistsPharmacologyArticleβ adrenoceptorchemistry.chemical_compoundInternal medicineReceptors Adrenergic betaMuscarinic acetylcholine receptorDrug DiscoveryMuscarinic acetylcholine receptor M4RAT URINARY-BLADDERMedicineAnimalsHumansCyclic adenosine monophosphateADRENERGIC RELAXATIONLung Diseases ObstructivePROTEIN-KINASE-CReceptorTRACHEAL SMOOTH-MUSCLEPharmacologybusiness.industryUrinary Bladder DiseasesMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2ACETYLCHOLINE-RELEASEAdrenergic beta-Agonistsmedicine.diseaseReceptors MuscarinicEndocrinologyNONNEURONAL CHOLINERGIC SYSTEMchemistryGUINEA-PIG TRACHEADrug Therapy CombinationCYCLIC ADENOSINE-MONOPHOSPHATECA2+-ACTIVATED K+ CHANNELAirwaybusinessUrinary bladder diseaseAUTORADIOGRAPHIC VISUALIZATIONAcetylcholinemedicine.drug
researchProduct